Clinical trials: IgG4 Related Disease
Immunoglobulin G4 Related Disease
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD).
- Trial name
- NCT04520451
- Testing
- rilzabrutinib, Glucocorticoids
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Immunoglobulin E-Mediated Food Allergy, Immunoglobulin G4-Related Disease
Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms
The aim of this study is to analyze a population with symptoms associated with adverse reactions to foodstuffs (ARFS). To determine the levels of food-specific immunoglobulin G4 (IgG4) and immunoglobulin E (IgE) antibody…
- Conditions
- Immunoglobulin E-Mediated Food Allergy, Immunoglobulin G4-Related Disease, Symptoms and Signs, Adverse Reaction to Food
- Trial name
- NCT05681975
- Testing
- Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Universidad Politecnica de Madrid
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic…
- Conditions
- Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies
- Trial name
- AYLo (NCT06696027)
- Testing
- Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Retroperitoneal Fibrosis, Autoimmune Pancreatitis
Rituximab in IgG4-RD: A Phase 1-2 Trial
The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.
- Conditions
- Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor
- Trial name
- NCT01584388
- Testing
- Rituximab
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497361
- Testing
- PRG-2311
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Autoimmune Diseases
Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
This study has been designed as a 18-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in active IgG4-RD patients with internal organ involvement…
- Trial name
- NCT05789017
- Testing
- Prednisone and Mycophenolate Mofetil, Mycophenolate Mofetil, Leflunomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
IgG4-Related Disease
A Study of IMM0306 in IgG4-Related Disease
The goal of this clinical trial is to learn if IMM0306 works to reduce the risk of disease relapse in participants with IgG4-related disease (IgG4-RD). It will also learn about the safety and tolerability of IMM0306.
- Trial name
- NCT07621939
- Testing
- IMM0306
- Volunteers
- 125 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis
Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids
This study evaluates corticosteroids in the treatment of obstructive jaundice in autoimmune pancreatitis and/or immunoglobulin G4 (IgG4)-related sclerosing cholangitis in adults.
- Conditions
- Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Obstructive Jaundice
- Trial name
- NCT02797665
- Testing
- corticosteroids, biliary stent
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
IgG4-related Disease
Plasmablast Detection From IgG4-Related Disease Patients
IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure.
- Trial name
- NCT03466970
- Where
- 2 sites in Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Autoimmune Diseases
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement…
- Trial name
- NCT05789030
- Testing
- glucocorticoid plus iguratimod, glucocorticoid plus leflunomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
IgG4-related Disease
Glucocorticoids in Patients With IgG4-RD
This is a randomized, open-label, single-center clinical trial to compare the efficacy and safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related Disease.
- Trial name
- NCT01758393
- Testing
- Prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Immunoglobulin G4-Related Disease, Janus Kinase Inhibitors
Tofacitinib in the Treatment of IgG4 Related Diseases
This study is a single centre, open label, randomized controlled study to compare the efficacy and safety between steroids plus tofacitinib and steroids alone in active IgG4-related diseases patients.
- Trial name
- NCT07827469
- Testing
- Tofacitinib 5mg Oral Tablet, Prednisone 5mg
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University People's Hospital
IgG4 Related Disease
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.
- Trial name
- NCT07298590
- Testing
- CD19/BCMA CAR NK
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
IgG4-related Disease
Tofatib Treatment for IgG4-related Disease
Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.
- Trial name
- NCT05625581
- Testing
- tofacitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
Rheumatoid Arthritis, Lupus Erythematosus, Systemic
Meir Medical Center Rheumatologic Biobank
Serum, synovial fluid and skin biopsies from patients will be collected to the biobank with rheumatoid diseases. These samples will later be used for clinical and basic research, following approval of each specific study by the…
- Conditions
- Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Systemic Sclerosis, IgG4-related Disease
- Trial name
- NCT03473912
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Meir Medical Center
IgG4 Related Disease
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
- Trial name
- NCT04602598
- Testing
- Zanubrutinib 80 MG
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew C. Baker